Last updated: November 13, 2026
Promethazine hydrochloride and dextromethorphan hydrobromide, commonly sold as promethazine DM oral solution, is a mature prescription cough product with low scientific differentiation, broad generic competition, and limited standalone financial disclosure. Its commercial value depends on manufacturing reliability, wholesaler access, seasonal respiratory illness, product availability, and state-level prescribing controls rather than patent exclusivity.
The product has no meaningful biosimilar risk because it is a small-molecule drug. Its principal competitive threats are other generic promethazine-dextromethorphan products, dextromethorphan-only products, benzonatate, guaifenesin combinations, and nonprescription cough remedies.
What is promethazine hydrochloride and dextromethorphan hydrobromide?
Promethazine DM is an oral liquid containing two active ingredients:
| Ingredient |
Pharmacologic role |
Common concentration |
| Promethazine hydrochloride |
Antihistamine and phenothiazine derivative with antiemetic and sedating activity |
6.25 mg per 5 mL |
| Dextromethorphan hydrobromide |
Centrally acting antitussive |
15 mg per 5 mL |
The product is prescribed for temporary relief of cough and upper-respiratory symptoms associated with allergy or the common cold. Promethazine carries a boxed warning against use in children younger than two years because of potentially fatal respiratory depression. Sedation, impaired alertness, respiratory effects, and drug-interaction risks constrain use in some patient groups.[1]
The combination is usually supplied as a syrup or oral solution. It is not a biologic, injectable product, extended-release system, or complex drug-device combination.
What is the FDA regulatory status of promethazine DM?
Promethazine DM is an FDA-regulated prescription product marketed primarily through generic approvals and abbreviated new drug applications. The active ingredients have long-established clinical and regulatory histories.
FDA status and dosage form
| Regulatory characteristic |
Assessment |
| FDA pathway |
Primarily generic prescription-drug pathway |
| Dosage form |
Oral syrup or oral solution |
| Route |
Oral |
| Prescription status |
Prescription-only |
| Pediatric restriction |
Contraindicated in children younger than two years |
| Controlled-substance status |
The combination is not a federally scheduled controlled substance |
| Reference-product dependence |
Generic products rely on FDA-established safety, efficacy, and bioequivalence standards |
| Main regulatory risk |
Label compliance, manufacturing quality, dosing errors, and adverse-event monitoring |
Dextromethorphan is available without a prescription when sold as a standalone cough suppressant in approved over-the-counter formulations. Combining it with promethazine changes the regulatory profile because promethazine is prescription-only and has material sedation and respiratory-depression risks.
State regulators and public-health authorities may impose additional controls on cough products containing dextromethorphan because of misuse by adolescents and young adults. These controls generally affect retail access and sales practices more than the underlying federal approval status.[2]
What patents protect promethazine DM?
The commercial product has limited patent protection because both active ingredients are old, well-established compounds. The original composition-of-matter patent estates for promethazine and dextromethorphan expired many years ago.
| Patent category |
Current commercial significance |
| Promethazine composition patents |
Expired |
| Dextromethorphan composition patents |
Expired |
| Combination composition patents |
No material active barrier identified for the standard immediate-release combination |
| Oral-solution formulation patents |
Limited relevance; standard formulations are broadly reproducible |
| Method-of-use patents |
Limited relevance for ordinary cough treatment |
| Manufacturing patents |
Potentially relevant to a supplier’s process, but not generally a market-wide barrier |
| Orange Book patent protection |
No widely recognized active patent estate blocking ordinary generic competition |
Promethazine DM therefore competes as a mature generic product. A manufacturer could hold process or formulation intellectual property, but such rights would usually protect a particular manufacturing method or product design rather than prevent competing manufacturers from selling standard promethazine-dextromethorphan oral solutions.
What is the Orange Book status of promethazine DM?
The FDA Orange Book is most relevant to approved prescription products and their listed patents. For a mature generic combination such as promethazine DM, the commercial market is generally driven by ANDA approvals rather than an active innovator patent listing.
The absence of a meaningful patent barrier has several consequences:
- Generic entry is not dependent on a patent challenge.
- Paragraph IV litigation is unlikely to be the principal market event.
- Multiple manufacturers can compete after regulatory approval.
- Pricing is exposed to wholesaler negotiations and pharmacy-benefit purchasing.
- Product differentiation must come from supply reliability, packaging, channel access, or formulation execution.
When does promethazine DM lose exclusivity?
Promethazine DM effectively lost market exclusivity long before the current generic market developed. The relevant commercial question is therefore not a future loss-of-exclusivity date but the degree of remaining generic concentration and supply competition.
| Exclusivity element |
Timing or status |
| Active-ingredient exclusivity |
Expired decades ago |
| Standard immediate-release combination exclusivity |
No material current exclusivity identified |
| New-drug exclusivity |
Not commercially relevant to the mature product |
| Generic competition |
Established |
| Future patent cliff |
Not expected |
| Commercial erosion |
Ongoing and largely complete |
The product’s revenue trajectory is not shaped by a single patent expiration date. It is shaped by recurring demand, product availability, manufacturer exits, raw-material costs, and periodic supply shortages.
How many manufacturers compete in the promethazine DM market?
The U.S. market has historically included multiple generic manufacturers, contract manufacturers, and private-label distributors. Product availability can vary by National Drug Code, bottle size, concentration, and supplier.
Typical competitive categories include:
- Generic pharmaceutical companies with their own ANDAs.
- Contract manufacturers supplying pharmacy and institutional channels.
- Private-label distributors.
- Regional suppliers serving hospitals and independent pharmacies.
- Manufacturers selling comparable promethazine-only or dextromethorphan-containing products.
The number of active suppliers can change quickly. A manufacturer may retain an FDA approval while reducing production, discontinuing a package size, or withdrawing from a low-margin product. FDA approval counts therefore do not always equal the number of suppliers actively competing in the market.[3]
What drives demand for promethazine DM?
Demand is seasonal and episodic rather than structurally high-growth.
Core demand drivers
| Driver |
Market effect |
| Winter respiratory infections |
Increases prescriptions and pharmacy demand |
| Allergy seasons |
Supports use in patients with upper-respiratory symptoms |
| Pediatric prescribing restrictions |
Reduces the eligible patient population |
| Opioid-containing cough-product restrictions |
Can shift some prescribing toward non-opioid alternatives |
| Dextromethorphan familiarity |
Supports physician and consumer recognition |
| Promethazine sedation |
Limits use in patients requiring alertness |
| Generic price |
Encourages substitution and suppresses manufacturer margins |
| Supply interruptions |
Can temporarily raise demand for alternative suppliers |
The combination benefits from the decline of opioid-containing cough products in some prescribing settings. Physicians may use promethazine DM as a non-opioid alternative, although dextromethorphan itself has misuse potential and is not a risk-free substitute.
Demand does not normally grow in proportion to the prevalence of chronic disease because promethazine DM is used for short-duration symptoms. Prescription volume is linked more closely to infection cycles, allergy activity, clinician preference, and payer coverage.
What is the financial trajectory of promethazine DM?
Promethazine DM is a low-to-moderate value generic product at the individual molecule level, but it can generate useful contribution margin for a manufacturer with efficient production and reliable distribution.
Public companies generally do not disclose revenue for this exact combination separately. Financial analysis must therefore rely on product-level prescription data, NDC sales data, manufacturer disclosures, and generic-market estimates rather than reported segment revenue.
Financial trajectory
| Period |
Expected market condition |
| Historical innovator period |
Higher pricing and limited competition |
| Generic-entry period |
Rapid price erosion and supplier expansion |
| Mature generic period |
Low unit prices, recurring demand, fragmented supply |
| Short-term shortage periods |
Temporary pricing and volume improvement for available suppliers |
| Long-term outlook |
Stable-to-declining nominal revenue with episodic seasonal spikes |
The market has four financial characteristics:
- Low price per treatment course. Standard oral solutions are inexpensive relative to patented prescription medicines.
- High substitutability. Pharmacies and wholesalers can often move between equivalent suppliers.
- Seasonal volume volatility. Respiratory illness can create sharp but temporary demand increases.
- Margin sensitivity. Packaging, freight, active-ingredient costs, quality testing, and channel rebates can materially affect profitability.
A company with excess liquid-manufacturing capacity may view promethazine DM as a portfolio-filling product. A company without scale may find the product unattractive because the market price does not support high development or manufacturing overhead.
What formulations are protected by promethazine DM patents?
The standard immediate-release syrup or oral solution is not protected by a commercially significant patent estate. Formulation differentiation is more likely to arise from manufacturing execution than from enforceable exclusivity.
Potential formulation variables include:
- Promethazine and dextromethorphan concentration.
- Sugar-containing versus sugar-free vehicle.
- Flavoring and taste-masking system.
- Preservative system.
- Bottle size and measuring device.
- Child-resistant packaging.
- Stability profile.
- Pourability and viscosity.
- Labeling and dosing instructions.
A sugar-free product or a formulation with improved taste may gain limited commercial preference, but these attributes generally do not create a durable barrier unless supported by enforceable intellectual property, regulatory exclusivity, or a strong distribution position.
Are there Paragraph IV challenges or patent lawsuits involving promethazine DM?
Paragraph IV litigation is not the central competitive issue for the ordinary promethazine-dextromethorphan combination. The product’s active ingredients and basic dosage form are mature, and generic products have been marketed for many years.
No major, market-defining patent settlement is associated with the standard product category. The more relevant legal risks are:
- Product-liability claims involving respiratory depression or sedation.
- Labeling disputes.
- Manufacturing-quality investigations.
- Recalls involving contamination, fill-volume errors, or stability failures.
- Trademark disputes involving brand presentation.
- Contract disputes between manufacturers and distributors.
- State enforcement involving controlled sales practices for dextromethorphan.
A manufacturer may still face litigation over a particular formulation, process, or labeling approach. Such disputes would usually affect one supplier rather than the entire market.
What generic entry risks exist for promethazine DM?
Generic entry risk is already realized. The market has passed from exclusivity protection to mature competition.
Key generic risks
| Risk |
Impact |
| Additional ANDA approvals |
Increases price pressure |
| Wholesaler consolidation |
Reduces supplier negotiating power |
| Pharmacy substitution |
Limits brand loyalty |
| Product discontinuation by a large supplier |
Can create short-term shortages |
| Active-ingredient cost increases |
Compresses gross margin |
| FDA manufacturing action |
Can remove supply from the market |
| Seasonal demand decline |
Creates inventory risk |
| Pediatric safety concerns |
Restricts prescribing and raises compliance costs |
| Alternative cough medicines |
Limits pricing power |
The main strategic risk is not a new generic launch but continued commoditization. Suppliers must maintain low manufacturing costs and avoid quality events while preserving sufficient inventory for seasonal demand.
How does promethazine DM compare with competing cough products?
| Product category |
Prescription status |
Main advantage |
Main limitation |
| Promethazine DM |
Prescription |
Combines antihistamine activity with antitussive activity |
Sedation, pediatric restrictions, generic pricing |
| Dextromethorphan alone |
Often OTC |
Broad availability and low cost |
Does not provide promethazine’s antihistamine effects |
| Benzonatate |
Prescription |
Non-opioid prescription antitussive |
Swallowing and safety concerns; different mechanism |
| Guaifenesin products |
Often OTC |
Expectorant positioning and broad retail presence |
Less direct antitussive effect |
| Opioid cough products |
Prescription, with regulatory controls |
Strong cough suppression |
Abuse, dependence, respiratory-depression risk |
| Antihistamine-only products |
OTC or prescription |
Useful when allergy symptoms predominate |
Limited cough-suppression effect |
Promethazine DM occupies a middle position: stronger prescription positioning than an OTC dextromethorphan product, but less commercial differentiation than a patented or extended-release therapy.
What manufacturing and intellectual-property barriers affect the market?
Manufacturing barriers are operational rather than patent-based. Oral liquids require validated mixing, uniformity testing, preservative control, fill-volume accuracy, packaging compatibility, and stability data.
Key manufacturing constraints include:
- Availability and quality of dextromethorphan hydrobromide and promethazine hydrochloride.
- Control of microbial contamination in aqueous products.
- Consistent suspension or solution uniformity.
- Reliable flavoring and preservative systems.
- Child-resistant packaging.
- Compliance with current good manufacturing practice requirements.
- Seasonal inventory planning.
- FDA inspection outcomes.
Manufacturing failures can have a larger short-term market effect than intellectual-property disputes. A recall or plant shutdown can shift volume rapidly to remaining suppliers, particularly during winter respiratory seasons.
Which companies are challenging promethazine DM?
The market is challenged primarily by generic pharmaceutical manufacturers and alternative product suppliers rather than by a single branded innovator.
Competitive pressure comes from:
- Generic oral-solution manufacturers.
- Contract development and manufacturing organizations.
- OTC cough-product companies.
- Producers of dextromethorphan-only products.
- Benzonatate manufacturers.
- Suppliers of guaifenesin combinations.
- Retail pharmacy private-label programs.
Because product-level revenue is not generally reported by large manufacturers, company-specific exposure requires NDC-level sales data or prescription-market datasets. Public filings typically aggregate promethazine DM within broader generic or prescription portfolios.
What is the geographic coverage of promethazine DM?
The product has broad U.S. availability through retail pharmacies, independent pharmacies, wholesalers, and institutional channels. International markets may use different brand names, concentrations, labeling requirements, and regulatory classifications.
Geographic differences affect:
- Prescription rules.
- Pediatric labeling.
- Dextromethorphan sales restrictions.
- Availability of oral-liquid formulations.
- Reimbursement and substitution practices.
- Local manufacturing and import requirements.
- Market access through national formularies.
The United States is a mature generic market. International demand is fragmented because cough-treatment standards and regulatory classifications differ by country.
What is the outlook for revenue and investment exposure?
The base-case outlook is stable to modestly declining revenue in nominal terms, interrupted by seasonal volume increases and temporary pricing events.
Base-case outlook
- No major patent cliff is expected because exclusivity has already expired.
- Unit demand should remain recurring but seasonal.
- Average selling prices should remain under pressure.
- Shortages can produce temporary upside for manufacturers with available inventory.
- Long-term growth is unlikely without a differentiated formulation or superior distribution position.
- Profitability will depend more on manufacturing efficiency than on pricing power.
Upside scenario
Revenue can improve if a supplier gains market share after a competitor’s discontinuation, resolves a shortage, secures a major wholesaler contract, or launches a differentiated sugar-free or improved-packaging formulation.
Downside scenario
Revenue can decline if additional suppliers enter, a major payer excludes the product, respiratory-season demand weakens, FDA quality action limits production, or physicians shift toward dextromethorphan-only and benzonatate products.
Key Takeaways
- Promethazine DM is a mature prescription generic containing promethazine hydrochloride and dextromethorphan hydrobromide.
- Its active ingredients and standard oral-liquid formulation have no meaningful current patent barrier.
- Patent expiration is not the main commercial event; generic commoditization is already established.
- No biosimilar risk exists because the product is a small molecule.
- Revenue is seasonal, fragmented, and generally not disclosed separately by public companies.
- Manufacturing reliability, wholesaler access, and supply continuity determine commercial performance.
- Generic price pressure limits long-term growth, while shortages can create short-term pricing opportunities.
- The main legal risks concern product liability, quality, labeling, and distribution rather than Paragraph IV litigation.
- The product remains commercially relevant as a non-opioid prescription cough option, but pediatric restrictions and sedation limit its use.
FAQs
Is promethazine DM still commercially relevant?
Yes. It remains a commonly recognized prescription cough product, but its commercial value comes from recurring seasonal demand rather than exclusivity or premium pricing.
Does promethazine DM have an active U.S. composition patent?
No material active composition patent protects the standard promethazine-dextromethorphan combination. The underlying active ingredients are old generic compounds.
Can a company obtain exclusivity for a new promethazine DM formulation?
Potentially, but exclusivity would depend on the formulation, regulatory pathway, and applicable intellectual-property rights. A standard syrup with routine excipients would face a high bar for meaningful differentiation.
Is promethazine DM subject to biosimilar competition?
No. Biosimilars apply to biologic products. Promethazine DM is a conventional small-molecule drug and competes through generic-drug approvals.
What would most improve a manufacturer’s promethazine DM economics?
Reliable supply during seasonal demand peaks, efficient oral-liquid manufacturing, low recall risk, strong wholesaler relationships, and a differentiated package or formulation would have the greatest effect on economics.
References
- U.S. Food and Drug Administration. (n.d.). Promethazine hydrochloride and dextromethorphan hydrobromide oral solution prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Dextromethorphan hydrobromide: Regulatory and safety information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. National Library of Medicine. (n.d.). DailyMed: Promethazine hydrochloride and dextromethorphan hydrobromide oral solution. DailyMed.
- U.S. Food and Drug Administration. (2024). Drugs@FDA and abbreviated new drug application resources. FDA.
